PF 06266047Alternative Names: PF06266047; PF6266047
Latest Information Update: 15 Jun 2016
At a glance
- Originator Pfizer
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
Most Recent Events
- 01 May 2016 Pfizer completes a phase I trial in Schizophrenia (In volunteers) in Belgium (NCT02539550)
- 08 Sep 2015 Pfizer plans a phase I trial in Undefined indication (In volunteers) in Belgium (NCT02539550)
- 01 Sep 2015 Preclinical trials in Undefined indication in Belgium (unspecified route)